5 Key Takeaways

• 1

  Neuroprotection is gaining attention in glaucoma due to limitations of current therapies that often fail to prevent disease progression.

• 2

  Research has identified the DLK/LZK signaling pathway as a key target for neuroprotective strategies in glaucoma treatment.

• 3

  Perceive Pharma is developing a sustained-release drug that shows promise in protecting retinal ganglion cells in animal studies.

• 4

  Advancements in AI and imaging techniques are enabling more efficient trial designs to test neuroprotective strategies in glaucoma.

• 5

  Patient compliance remains a significant challenge in glaucoma management, highlighting the need for innovative treatment approaches.